Literature DB >> 24453761

Facilitating medication adherence in patients with multiple sclerosis.

Gina Remington1, Yolanda Rodriguez1, Diana Logan1, Caroline Williamson1, Katherine Treadaway1.   

Abstract

This article reviews adherence to medication in multiple sclerosis (MS) patients from the perspective of nurse and social worker authors. It reviews data on patient adherence and offers practical, evidence-based strategies that health-care providers can use to facilitate adherence. In addition, it examines how emerging MS therapies may affect patient adherence and associated interventions. To promote adherence, interventions need to incorporate new and creative approaches. A proactive approach includes assessing patient needs and lifestyle before the start of medication and selecting the most appropriate disease-modifying therapy for each individual patient. Including multidisciplinary expertise and services in the treatment plan can be part of a comprehensive, holistic approach to helping patients and families. Optimization of health-care provider roles is likely to facilitate improved adherence.

Entities:  

Year:  2013        PMID: 24453761      PMCID: PMC3883032          DOI: 10.7224/1537-2073.2011-038

Source DB:  PubMed          Journal:  Int J MS Care        ISSN: 1537-2073


  33 in total

Review 1.  Motivational interviewing: improving patient education.

Authors:  Bonnie Gance-Cleveland
Journal:  J Pediatr Health Care       Date:  2007 Mar-Apr       Impact factor: 1.812

Review 2.  Natural history of multiple sclerosis: have available therapies impacted long-term prognosis?

Authors:  Maria Trojano; Damiano Paolicelli; Carla Tortorella; Piero Iaffaldano; Guglielmo Lucchese; Vita Di Renzo; Mariangela D'Onghia
Journal:  Neurol Clin       Date:  2011-05       Impact factor: 3.806

Review 3.  Quantifying the role of natalizumab in health and economic outcomes in multiple sclerosis.

Authors:  David W Brandes; Fadia T Shaya; Michael W Pill
Journal:  Am J Manag Care       Date:  2010-06       Impact factor: 2.229

4.  Injection of interferon-beta in the morning decreases flu-like syndrome in many patients with multiple sclerosis.

Authors:  Yann Nadjar; Emilie Coutelas; Pauline Prouteau; Fabienne Panzer; Danièle Paquet; Claude Saint-Val; Alain Créange
Journal:  Clin Neurol Neurosurg       Date:  2011-01-26       Impact factor: 1.876

5.  Adherence to disease-modifying therapies in spanish patients with relapsing multiple sclerosis: two-year interim results of the global adherence project.

Authors:  E Arroyo; C Grau; C Ramo-Tello; J Parra; O Sánchez-Soliño
Journal:  Eur Neurol       Date:  2011-01-04       Impact factor: 1.710

6.  A comparative study of self-efficacy in men and women with multiple sclerosis.

Authors:  Cira Fraser; Sue Polito
Journal:  J Neurosci Nurs       Date:  2007-04       Impact factor: 1.230

7.  Factors that influence adherence with disease-modifying therapy in MS.

Authors:  Katherine Treadaway; Gary Cutter; Amber Salter; Sharon Lynch; James Simsarian; John Corboy; Douglas Jeffery; Bruce Cohen; Ken Mankowski; Joseph Guarnaccia; Lawrence Schaeffer; Roy Kanter; David Brandes; Charles Kaufman; David Duncan; Ellen Marder; Arthur Allen; John Harney; Joanna Cooper; Douglas Woo; Olaf Stüve; Michael Racke; Elliot M Frohman
Journal:  J Neurol       Date:  2009-04-27       Impact factor: 4.849

8.  Optimizing the benefit of multiple sclerosis therapy: the importance of treatment adherence.

Authors:  Francesco Patti
Journal:  Patient Prefer Adherence       Date:  2010-02-04       Impact factor: 2.711

Review 9.  Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?

Authors:  Alessandra Lugaresi
Journal:  Expert Opin Drug Deliv       Date:  2009-09       Impact factor: 6.648

10.  Alemtuzumab vs. interferon beta-1a in early multiple sclerosis.

Authors:  Alasdair J Coles; D Alastair S Compston; Krzysztof W Selmaj; Stephen L Lake; Susan Moran; David H Margolin; Kim Norris; P K Tandon
Journal:  N Engl J Med       Date:  2008-10-23       Impact factor: 91.245

View more
  23 in total

Review 1.  Glatiramer Acetate 40 mg/mL in Relapsing-Remitting Multiple Sclerosis: A Review.

Authors:  Kate McKeage
Journal:  CNS Drugs       Date:  2015-05       Impact factor: 5.749

Review 2.  Treatment-Related Progressive Multifocal Leukoencephalopathy in Multiple Sclerosis: A Comprehensive Review of Current Evidence and Future Needs.

Authors:  Emanuele D'Amico; Aurora Zanghì; Carmela Leone; Hayrettin Tumani; Francesco Patti
Journal:  Drug Saf       Date:  2016-12       Impact factor: 5.606

3.  The Patient Activation Measure: a validation study in a neurological population.

Authors:  Tanya L Packer; George Kephart; Setareh Ghahari; Åsa Audulv; Joan Versnel; Grace Warner
Journal:  Qual Life Res       Date:  2015-01-06       Impact factor: 4.147

4.  Assessing Barriers to Adherence with the Use of Dimethyl Fumarate in Multiple Sclerosis.

Authors:  Angela Aungst; Lise Casady; Crystal Dixon; Janice Maldonado; Natalie Moreo; Laurie Pearsall; Derrick Robertson
Journal:  Clin Drug Investig       Date:  2020-01       Impact factor: 2.859

5.  Long-term fingolimod treatment in two pediatric patients with multiple sclerosis.

Authors:  Giovanna Borriello; Carlo Pozzilli
Journal:  Neurol Sci       Date:  2021-03-10       Impact factor: 3.307

6.  Probability discounting of treatment decisions in multiple sclerosis: associations with disease knowledge, neuropsychiatric status, and adherence.

Authors:  Jared M Bruce; Amanda S Bruce; Sharon Lynch; Joanie Thelen; Seung-Lark Lim; Julia Smith; Delwyn Catley; Derek D Reed; David P Jarmolowicz
Journal:  Psychopharmacology (Berl)       Date:  2018-09-22       Impact factor: 4.530

7.  Impact of Shared Decision Making on Disease-Modifying Drug Adherence in Multiple Sclerosis.

Authors:  Aliza Ben-Zacharia; Meagan Adamson; Allison Boyd; Paula Hardeman; Jennifer Smrtka; Bryan Walker; Tracy Walker
Journal:  Int J MS Care       Date:  2018 Nov-Dec

8.  Impact of Switching to Fingolimod Versus Injectable Disease-Modifying Therapy Cycling on Risk of Multiple Sclerosis-Related Relapses: A Retrospective Analysis.

Authors:  Maria Cecilia Vieira; Yunfeng Li; Xiangyi Meng; Huanxue Zhou; Olivia Wenxian Piao; Christen Kutz; Devon Conway
Journal:  Int J MS Care       Date:  2020-04-28

9.  An At-home Positive Psychology Intervention for Individuals with Multiple Sclerosis: A Phase 1 Randomized Controlled Trial.

Authors:  Melanie E Freedman; Brian C Healy; Jeff C Huffman; Tanuja Chitnis; Howard L Weiner; Bonnie I Glanz
Journal:  Int J MS Care       Date:  2020-08-31

Review 10.  Inclusion of People with Disabilities in Research to Improve Medication Adherence: A Systematic Review.

Authors:  Jaclyn K Schwartz; Elizabeth Unni
Journal:  Patient Prefer Adherence       Date:  2021-07-26       Impact factor: 2.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.